Toronto-Dominion Bank vs Viatris Inc — how do they compare? Toronto-Dominion Bank trades at $114.14 (market cap $185.79B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Toronto-Dominion Bank is far larger — about 9.3× Viatris Inc's market cap, and Toronto-Dominion Bank pays the higher dividend (2.84%). Which is the better fit depends on your goals — on Pluang, investors hold Toronto-Dominion Bank for 84 Days and Viatris Inc for 57 Days on average.
| TD | VTRS | |
|---|---|---|
Market Cap | $185.79B | $20.03B |
Volume | 3,263,867 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $124.80 | $18.27 |
52-Week Low | $78.32 | $9.74 |
Typical Hold Time | 84 Days | 57 Days |
Enterprise Value | $559.06B | $32.15B |
Dividend Yield | 2.84% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
TD stock trades at $113.87, down 3.65% on the day, with bearish technical signals but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.98 exceeding expectations by 13.8%. Recent developments include a $10 billion share buyback program and a $108 billion commitment to Canadian infrastructure. Analyst consensus remains positive with 53% buy ratings and no sell recommendations.
TD presents a mixed investment case with strong profitability metrics (24.9% net margin, 13.6% ROE) offset by bearish technical indicators and volatile cash flow patterns. The stock's current valuation at 17.4x P/E appears reasonable given earnings growth, while the aggressive capital return program signals management confidence. Key risks include interest rate sensitivity and ongoing AML remediation efforts.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →